Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF

Not yet recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Fatty Liver Disease, Nonalcoholic
Interventions
PROCEDURE

bariatric surgery (BS)

bariatric surgery (BS) is a very attractive choice for severely obese patients. After bariatric surgery, long-term weight loss (15%-25%) and diabetes remission can occur \[16\], as well as long-term mortality, cardiovascular events and tumor occurrence \[17\]. Regardless of the surgical procedure used for weight loss surgery, studies have shown that weight loss surgery can significantly reduce the liver NAFLD activity score (from 5 to 1), and 33.8% of patients have reduced liver fibrosis \[18\]. The follow-up results for a longer period of time (10 years) also indicate that weight loss surgery significantly reduces the occurrence of major adverse outcomes related to liver cirrhosis, liver cancer, liver transplantation, and liver related deaths

All Listed Sponsors
lead

Qianfoshan Hospital

OTHER

NCT06097338 - Quantitative US for Evaluation of Hepatic Steatosis in MAFLD With UDFF | Biotech Hunter | Biotech Hunter